SG11201703939XA - Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition - Google Patents
Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix depositionInfo
- Publication number
- SG11201703939XA SG11201703939XA SG11201703939XA SG11201703939XA SG11201703939XA SG 11201703939X A SG11201703939X A SG 11201703939XA SG 11201703939X A SG11201703939X A SG 11201703939XA SG 11201703939X A SG11201703939X A SG 11201703939XA SG 11201703939X A SG11201703939X A SG 11201703939XA
- Authority
- SG
- Singapore
- Prior art keywords
- compositions
- preventing
- conditions
- methods
- extracellular matrix
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyridine Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicinal Preparation (AREA)
- Thiazole And Isothizaole Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462080784P | 2014-11-17 | 2014-11-17 | |
PCT/US2015/061118 WO2016081475A1 (fr) | 2014-11-17 | 2015-11-17 | Compositions et procédés pour prévenir ou traiter des maladies, affections ou processus caractérisés par une prolifération aberrante des fibroblastes et un dépôt de matrice extracellulaire |
US14/943,752 US10500249B2 (en) | 2014-11-17 | 2015-11-17 | Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201703939XA true SG11201703939XA (en) | 2017-06-29 |
Family
ID=55960752
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201703939XA SG11201703939XA (en) | 2014-11-17 | 2015-11-17 | Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition |
Country Status (13)
Country | Link |
---|---|
US (1) | US10500249B2 (fr) |
EP (1) | EP3220943A4 (fr) |
JP (1) | JP2018501201A (fr) |
KR (1) | KR20170083063A (fr) |
CN (1) | CN107106650A (fr) |
AU (1) | AU2015350151A1 (fr) |
BR (1) | BR112017010238A2 (fr) |
CA (1) | CA2967621A1 (fr) |
MX (1) | MX2017006372A (fr) |
RU (1) | RU2017121090A (fr) |
SG (1) | SG11201703939XA (fr) |
WO (1) | WO2016081475A1 (fr) |
ZA (1) | ZA201703305B (fr) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3072903A1 (fr) * | 2017-09-08 | 2019-03-14 | Bristol-Myers Squibb Company | Facteur de croissance des fibroblastes 21 (fgf-21) modifie destine a une utilisation dans des methodes de traitement de la steatohepatite non alcoolique (nash) |
EP3692073A4 (fr) * | 2017-10-03 | 2021-05-26 | Cedars-Sinai Medical Center | Procédés de ciblage de la voie pd1 du point de contrôle immunitaire pour le traitement de la fibrose pulmonaire |
CN108795935B (zh) * | 2018-05-23 | 2022-06-21 | 中国农业科学院上海兽医研究所(中国动物卫生与流行病学中心上海分中心) | 日本血吸虫SjELAV-like 1基因的siRNA及其应用 |
CN110575540B (zh) * | 2018-06-07 | 2021-11-02 | 中山大学附属第六医院 | Pdgf抑制剂用于制备治疗肠道炎症疾病的药物方面的用途 |
CN113134116B (zh) * | 2020-01-20 | 2022-09-06 | 山东威高宏瑞医学科技有限公司 | 内镜微创手术用的填充组合物及填充制剂 |
CN113952821A (zh) * | 2021-07-22 | 2022-01-21 | 上海安居乐环保科技股份有限公司 | 一种罐区装卸区废气综合治理方法及系统 |
CN113730551B (zh) * | 2021-09-02 | 2022-11-25 | 徐州医科大学 | Mmi-0100短肽化合物在制备胆汁淤积性肝病治疗药物中的应用 |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1521000A (en) | 1975-06-13 | 1978-08-09 | Syntex Puerto Rico Inc | Inhalation device |
US4192309A (en) | 1978-09-05 | 1980-03-11 | Syntex Puerto Rico, Inc. | Inhalation device with capsule opener |
US4227522A (en) | 1978-09-05 | 1980-10-14 | Syntex Puerto Rico, Inc. | Inhalation device |
ZW21483A1 (en) | 1982-10-08 | 1985-05-08 | Glaxo Group Ltd | Device for administering medicaments to patients |
US4778054A (en) | 1982-10-08 | 1988-10-18 | Glaxo Group Limited | Pack for administering medicaments to patients |
BR8603576A (pt) | 1985-07-30 | 1987-03-04 | Glaxo Group Ltd | Dispositivos para administrar medicamentos a pacientes |
JPH05963A (ja) | 1990-04-13 | 1993-01-08 | Toray Ind Inc | ポリペプチド類組成物 |
US6331318B1 (en) | 1994-09-30 | 2001-12-18 | Emisphere Technologies Inc. | Carbon-substituted diketopiperazine delivery systems |
US5352461A (en) | 1992-03-11 | 1994-10-04 | Pharmaceutical Discovery Corporation | Self assembling diketopiperazine drug delivery system |
US6582728B1 (en) | 1992-07-08 | 2003-06-24 | Inhale Therapeutic Systems, Inc. | Spray drying of macromolecules to produce inhaleable dry powders |
CA2178729A1 (fr) | 1993-12-09 | 1995-06-15 | Eric B. Kmiec | Composes et procedes pour realiser des mutations dirigees sur le site dans des cellules eucaryotes |
US6428771B1 (en) | 1995-05-15 | 2002-08-06 | Pharmaceutical Discovery Corporation | Method for drug delivery to the pulmonary system |
JP2002540850A (ja) | 1999-04-05 | 2002-12-03 | ファーマシューティカル ディスカバリー コーポレイション | 微粉形成のための方法 |
ATE545652T1 (de) | 1999-06-29 | 2012-03-15 | Mannkind Corp | Reinigung und stabilisierung von proteinen und peptiden in pharmaceutischen agentien |
DK1786784T3 (da) | 2004-08-20 | 2011-02-14 | Mannkind Corp | Katalyse af diketopiperazinsyntese |
EP1781254A2 (fr) | 2004-08-23 | 2007-05-09 | Mannkind Corporation | Administration pulmonaire d'inhibiteurs de phosphodiesterase de type 5 |
PL2322180T3 (pl) | 2004-08-23 | 2015-10-30 | Mannkind Corp | Sole diketopiperazyny do dostarczania leków |
RU2394550C2 (ru) | 2005-09-14 | 2010-07-20 | Маннкайнд Корпорейшн | Способ получения лекарственной композиции, основанный на увеличении сродства поверхностей кристаллических микрочастиц к активным агентам |
EP2497484A3 (fr) | 2006-02-22 | 2012-11-07 | MannKind Corporation | Procédé pour améliorer les propriétés pharmaceutiques de microparticules comprenant de la dicétopipérazine et un agent actif |
EP2606903B1 (fr) * | 2007-01-10 | 2016-09-14 | Purdue Research Foundation | Inhibiteurs polypeptidiques de la kinase hsp27 et leurs utilisations |
NL1033850C2 (nl) | 2007-05-15 | 2008-11-18 | 3Force B V | Brandersysteem met voorgemengde branders en vlam-overdrachtsmiddelen. |
EP2185698B1 (fr) | 2007-08-07 | 2015-04-22 | Purdue Research Foundation | Inhibiteurs de kinase et leurs utilisations |
BRPI0919759A2 (pt) * | 2008-10-20 | 2017-03-21 | Moerae Matrix Inc | polipeptídeos para tratamento e prevenção de adesões |
KR101779616B1 (ko) * | 2008-12-10 | 2017-09-18 | 퍼듀 리서치 파운데이션 | 키나아제의 세포-침투성 펩티드-기초된 저해물질 |
EP2575855A4 (fr) | 2010-05-24 | 2014-03-12 | Moerae Matrix Inc | Procédé de traitement ou de prévention d'une rupture de greffe vasculaire |
CN111110850A (zh) * | 2011-04-12 | 2020-05-08 | 莫伊莱麦屈克斯公司 | 用于预防或治疗以成纤维细胞异常增殖及细胞外基质沉积为特征的疾病的组合物和方法 |
WO2013134636A1 (fr) * | 2012-03-09 | 2013-09-12 | Purdue Research Foundation | Compositions et procédés d'administration de peptides inhibiteurs de kinases |
EP2931272A1 (fr) * | 2012-12-12 | 2015-10-21 | The Charlotte-Mecklenburg Hospital Authority D/B/A Carolinas Healthcare System | Procédés de traitement de la fibrose hépatique et de maladies associées par régulation de l'activité rev-erb |
-
2015
- 2015-11-17 WO PCT/US2015/061118 patent/WO2016081475A1/fr active Application Filing
- 2015-11-17 CA CA2967621A patent/CA2967621A1/fr not_active Abandoned
- 2015-11-17 CN CN201580062363.0A patent/CN107106650A/zh active Pending
- 2015-11-17 AU AU2015350151A patent/AU2015350151A1/en not_active Abandoned
- 2015-11-17 EP EP15861651.6A patent/EP3220943A4/fr not_active Withdrawn
- 2015-11-17 JP JP2017526674A patent/JP2018501201A/ja active Pending
- 2015-11-17 KR KR1020177014506A patent/KR20170083063A/ko unknown
- 2015-11-17 RU RU2017121090A patent/RU2017121090A/ru not_active Application Discontinuation
- 2015-11-17 BR BR112017010238-2A patent/BR112017010238A2/pt not_active Application Discontinuation
- 2015-11-17 US US14/943,752 patent/US10500249B2/en not_active Expired - Fee Related
- 2015-11-17 SG SG11201703939XA patent/SG11201703939XA/en unknown
- 2015-11-17 MX MX2017006372A patent/MX2017006372A/es unknown
-
2017
- 2017-05-12 ZA ZA2017/03305A patent/ZA201703305B/en unknown
Also Published As
Publication number | Publication date |
---|---|
ZA201703305B (en) | 2020-05-27 |
BR112017010238A2 (pt) | 2018-02-06 |
AU2015350151A1 (en) | 2017-06-01 |
US20160136234A1 (en) | 2016-05-19 |
JP2018501201A (ja) | 2018-01-18 |
KR20170083063A (ko) | 2017-07-17 |
CA2967621A1 (fr) | 2016-05-26 |
EP3220943A1 (fr) | 2017-09-27 |
WO2016081475A1 (fr) | 2016-05-26 |
RU2017121090A3 (fr) | 2019-06-10 |
US10500249B2 (en) | 2019-12-10 |
CN107106650A (zh) | 2017-08-29 |
MX2017006372A (es) | 2017-08-21 |
RU2017121090A (ru) | 2018-12-20 |
EP3220943A4 (fr) | 2018-08-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1255005A1 (zh) | 用於預防或治療以成纖維細胞異常增殖及細胞外基質沉積為特徵的疾病的組合物和方法 | |
ZA201703305B (en) | Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition | |
SG11201705093UA (en) | Composition for treating il-6-related diseases | |
PT3261640T (pt) | Agonistas de 5ht para tratamento de distúrbios de epilepsia | |
PL3167096T3 (pl) | Dwuetapowy sposób nanoszenia | |
EP3501527C0 (fr) | Composition permettant de prévenir ou de traiter un trouble mental, contenant une vésicule dérivée de bactéries d'une espècelactobacillus | |
ZA201700416B (en) | Methods for treating or preventing ophthalmological conditions | |
IL250715A0 (en) | Preparations and methods for the treatment of cultural disorders | |
HK1245084A1 (zh) | 用於治療癌症的包含金屬乳酸鹽的藥物組合物 | |
HK1244211A1 (zh) | 治療、預防或降低皮膚感染風險的方法 | |
EP3275450A4 (fr) | Composition pharmaceutique pour prévenir ou traiter des maladies inflammatoires, contenantlactococcus chungangensis | |
HK1213937A1 (zh) | 耐久抗微生物塗料組合物 | |
SG11201701135WA (en) | Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition | |
EP3326638A4 (fr) | Composition pharmaceutique pour la prévention ou le traitement de maladies médiées par il-6 comprenant un extrait de fleur derosa rugosa | |
GB201515985D0 (en) | Deposition process | |
HK1232128A1 (zh) | 用於預防或治療皮疹的藥物組合物 | |
SG11201704701YA (en) | Pharmacotherapy for preventing or treating glaucoma | |
KR101894521B9 (ko) | 흉터치료를 위한 국소용 약학적 조성물 | |
PT3565592T (pt) | Tratamento de doenças metabólicas através da inibição da ativação da miostatina | |
EP3305293A4 (fr) | Procédé de traitement ou de prévention de la néphropathie diabétique | |
EP3210602A4 (fr) | Composition destinée à prévenir ou à traiter les maladies neurodégénératives, contenant de la ramaline | |
EP3354271A4 (fr) | Agent de traitement de maladies arthrologiques |